| The Corporate Environment, Health and Safety
department reports directly to GlaxoSmithKline's General Counsel,
Rupert Bondy and has a dotted line reporting relationship to the
President of Global Manufacturing and Supply, the GSK manufacturing
organisation. This places the Vice President, Corporate Environment,
Health and Safety on both the Legal Management Team and the Global
Manufacturing and Supply Executive Team illustrating the emphasis
placed on EHS in GlaxoSmithKline.
CEHS
Vision: To be the undisputed leader in EHS in
the pharmaceutical industry, contributing to sustainable,
competitive business advantage for GlaxoSmithKline
CEHS Mission
In order to achieve its vision, CEHS will provide:
- leadership for the integrated,
global effort within GlaxoSmithKline on key EHS issues
- governance of EHS performance
- support for GlaxoSmithKline businesses
with tools, technology, information and knowledge
- innovation and continuous improvement
for unified EHS systems and approaches
|
The EHS Strategy and Advocacy team co-ordinates
the EHS Plan for Excellence, the strategic approach to environment,
health and safety that will enable GlaxoSmithKline to achieve its
EHS aspirations. This includes overseeing stakeholder engagement
and working with external partner organisations on EHS. The team
also identifies emerging issues and works with government and regulatory
bodies to influence the development of regulations.
The EHS Product Stewardship
team promotes the
ethical management of environment, health and safety throughout
the life-cycles of GlaxoSmithKline products. This group develops,
implements and supports
key programmes in occupational hygiene, process safety and environmental
controls. It also champions sustainable EHS practices and works
with research & development and the New Product Supply organisation
to identify potential EHS life-cycle issues early in the development
process. Once the team assesses EHS issues, it recommends measures
to mitigate, control, and manage EHS risks. The team provides
technical information and guidance and also recommends
to research & development strategies for developing manufacturing
processes that use resources efficiently and that minimise emissions.
And it helps by developing and promoting innovative tools, systems
and methodologies.
The Hazard Assessment and Communication team
assesses and communicates environment, health and safety hazards
associated with manufacture, distribution and disposal of GlaxoSmithKline
materials and products. This team focuses on materials for research
and development in the Pharmaceuticals, Biologicals and Consumer
Healthcare businesses and especially on all new products. Its task
is to provide information that will support safe and effective controls
for protection of employees and the environment. In 2003, it placed
a major emphasis on identifying and filling gaps in hazard information
resulting from merger-related transfers of products within the manufacturing
network. By doing this it was able to ensure the availability of
consistent, high-quality hazard information for all GlaxoSmithKline
materials.
The newly formed EHS Commercial Support team
extends the traditional work of CEHS beyond research & development
and manufacturing into GlaxoSmithKline's Commercial businesses.
The mission of the team is to add value to Commercial operations
by improving their effectiveness through reducing EHS risks. The
team is committed to building and strengthening relationships and
understanding the business and EHS needs of the Commercial groups.
The team's aim is to become a strategic business partner through
providing appropriate and relevant programmes and services and thereby
assist this business sector in improving EHS performance.
The EHS Global Audit team delivers an internal
audit programme, in collaboration with Employee Health Management,
for all manufacturing, research & development and key office and
warehouse locations. It also manages a number of strategic projects.
In addition, this team performs risk-based assessments of key contract
manufacturers and suppliers and EHS due diligence assessments for
acquisitions and divestitures. In all cases the aim is to ensure
that EHS risks and impacts are managed effectively and to identify
opportunities to reduce risks and contribute to continuous improvement.
The EHS Reporting team collects and analyses data
from all operations for reporting to internal and external stakeholders.
It evaluates data contributed by all operations and uses the information
to assess the effectiveness of EHS programmes and drive continuous
improvement. The team also provides EHS information management software
that can be used to manage EHS programmes and measure improvement
and progress to targets. In addition, it manages EHS reward, recognition
and awareness programmes that are the parts of the overall GlaxoSmithKline
EHS Framework devoted to motivating employees, raising awareness
and driving continuous improvement.
The Research & development EHS Group reports
with a dotted line to the VP Corporate Environment, Health and Safety.
This group facilitates integration of EHS into the agenda of the
research & development sector of the business and supports a unified
and consistent approach to EHS across the company.
|
